Kyoto Trial to Evaluate the Safety and Efficacy of Tacrolimus in the iPSC-based Therapy for Parkinson's Disease

General Information

Description To evaluate the safety and efficacy of tacrolimus in patients with Parkinson's disease after transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors into the corpus striatum.
Clinical trials phase Phase 3
Start date (estimated) 2018-08-01
End date (estimated) 2023-12-31
Clinical feature
Label Parkinson's disease
Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

ICTRP weblink
Other study identifiers
Name UMIN000033565
Description UMIN Clinical Trials Registry (UMIN-CTR)
Source weblink
Public contact
First name Nobukatsu
Last name Sawamoto
Phone 075-751-3771
City Kyoto
Address freetext 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507
Sponsors Kyoto University Hospital


Which differentiated cell type is used
Label dopaminergic neuron
Description A neuron that releases dopamine as a neurotransmitter.


Recruitment Status Suspended
Estimated number of participants 7